Pathophysiology of pulmonary hypertension due to lung disease

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 2, 2003, Pages 131-138

  Presberg, Kenneth W ^a   Dincer, H Erhan ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; HYPOXIA; LUNG DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; ANOXIA; CHRONIC DISEASE; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 12244259694     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200303000-00007     Document Type: Review

References (87)

1. Burrows B, Kettel NJ, Niden AH, et al: Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972, 286:912-918.
2. Tockman MS, Permutt S, Kennedy T: Prognosis in chronic obsturctive pulmonary disease. N Engl J Med 1983, 308:992-993.
3. Fishman A: State of the art: chronic cor pulmonale. Am Rev Respir Dis 1976, 114:775-794.
4. Incalzi RA, Fuso L, De Rosa M, et al: Electrocardiographic signs of chronic cor pulmonale: A negative prognostic finding in chronic obstructive pulmonary disease. Circulation 1999, 99:1600-1605.
5. Executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France. September 6-10, 1998. Available at: http://www. who.int/ncd/cvd/pph.html. Accessed December 9, 2002.
6. Matthay RA, Schwarz MI, Ellis JH Jr, et al: Pulmonary artery hypertension in chronic obstrucive pulmonary disease: chest radiographic assessment. Invest Radiol 1981, 16:95-100.
7. Tan RT, Kuzo R, Goodman LR, et al: Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest 1998, 113:1250-1256.
8. Himelman RB, Struve SN, Brown JK, et al: Improved recognition of cor pulmonale in patients with severe chronic obstructive pulmonary disease. Am J Med 1988, 84:891-898.
9. Agusti A, Roca J, Gea J, et al: Mechanisms of gas exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991, 143:219-225.
10. Boushy JF, North LB: Hemodynamic changes in chronic obstructive pulmonary disease. Chest 1977, 72:565-570.
11. Fraser DL, Tullis DE, Sasson Z, et al: Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 1999, 115:1321-1328.
12. Stevens D, Sharma K, Szidon P, et al: Severe pulmonary hypertension associated with COPD. Ann Transplant 2000, 5:8-12.
13. Lane KB, Machada RD, Pauciulo MW, et al: Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000, 26:81-84.
14. Deng Z, Morse JH, Slager SL, et al: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor II gene. Am J Hum Genet 2000, 67:737-744.
15. Thompson JR, Machado RD, Pauciulo MW, et al: Sporadic primary pulmonary hypertension is associated with germline mutation of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000, 37:741-745.
16. Trembath RC, Thomson JR, Machado RD, et al: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001, 345:325-334.
17. Stewart DJ, Levy RD, Cernacek P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991, 114:464-469.
18. Weitzenblum E, Sautegeau A, Ehrhart M, et al: Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984, 130:993-998.
19. Naeije R: Should pulmonary hypertension be treated in chronic obstructive pulmonary disease? In The Diagnosis and Treatment of Pulmonary Hypertension. Edited by Weir EK, Archer SI, Reeves JT. Mount Kisco: 1992, Futura Publishing Inc.;1992:209-239.
20. Fletcher EC, Luckett RA, Miller T, et al: Pulmonary vascular hemodynamics in chronic lung disease patients with and without oxyhemoglobin desaturation during sleep. Chest 1989, 95:757-764.
21. 2 desaturation and daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia. Eur Respir J 1997, 10:1730-1735.
22. McGuire M, Bradford A: Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats. Eur Respir J 2001, 18:279-285.
23. Edwards WD: The pathology of secondary pulmonary hypertension. In The Pulmonary Circulation. Edited by Fishman A. Philadelphia: University of Pennsylvania Press;1990:329-342.
24. Pietra EA, Edwards WD, Kay JM, et al: Histopathology of primary pulmonary hypertension: a qualitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute primary pulmonary hypertension registry. Circulation 1989, 80:1198-1206.
25. Lee SD, Shoyer KR, Markham NE, et al: Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998, 101:927-934.
26. Tuder RM, Groves BM, Badesch DB, et al: Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994, 144:275-285.
27. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981, 1:681-686.
28. Continuous or Nocturnal Oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980, 93:391-398.
29. Weitzenbulm E, Sautegeau A, Ehrhart M, et al: Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985, 131:493-498.
30. Meyrick B, Reid L: The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study. Lab Invest 1978, 38:188-200.
31. Meyrick B, Reid L: Endothelial and subintimal changes in rat hilar pulmonary artery during recovery from hypoxia. A quantitative ultrastructural study. Lab Invest 1980, 42:603-615.
32. Jeffrey TK, Wanstall JC: Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacology & Therapeutics 2001, 92:1-20.
33. McQuillan LP, Leung GK, Marsden PA, et al: Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994, 267:H1921-H1927.
34. Wang J, Juhaszova M, Rubin LJ, Yuan XJ: Hypoxia inhibits gene expression of voltage gated potassium channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997, 100;2347-2353.
35. Smirnov S, Robertson T, Ward J, et al: Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells. Am J Physiol 1994, 266: H365-H370.
36. Wang J, Juhaszova M, Rubin LJ, et al: Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997, 100:2347-2353.
37. Li H, Chen SJ, Chen YF, et al: Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 1994, 77:1451-1459.
38. Dawes KE, Peacock AJ, Gray AJ, et al: Characterization of fibroblast mitogens and chemoattractants produced by endothelial cells exposed to hypoxia. Am J Respir Cell Mol Biol 1994, 10:552-559.
39. Madden MD, Vender RL, Friedman M: Effect of hypoxia on prostacyclin production in cultured pulmonary artery endothelium. Prostaglandins 1986, 31:1049-1062.
40. Zamora MA, Dempsey EC, Walchak SJ, Stelzner TJ: BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 1993, 9:429-433.
41. Maruyama D, Ye DL, Woo M, et al: Chronic hypoxic pulmonary hypertension in rats and increased elastolyitc activity. Am J Physiol 1997, 272:H517-H524.
42. Eddahibi S, Hansoun N, Lanfumey L, et al: Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydoxytryptamine transporter gene. J Clin Invest 105, 1555-1562.
43. Eddahibi S, Fabre V, Boni C, et al: Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relation with the mitogenic action of serotonin. Circ Res 1999, 84:329-326.
44. Morrell NW, Atochina EN, Morris KG, et al: Angiotensin converting enzyme expression in increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 1995, 96:1823-1833.
45. Morell NW, Morris KG, Stenmark KR, et al: Role of aniotensin-converting enzyme and aniotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995, 269:1186-1194.
46. Meyrick B: The pathology of pulmonary hypertension. Clin Chest Med 2001, 22:393-404.
47. Badesch DB, Orton EC, Zapp L, et al: Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol 1989, 1:489-498.
48. Fagan DA, Fouty BW, Tyler RC, et al: The pulmonary circulation of mice with either homozygous or heterozygous disruption of endothelial nitric oxide synthase is hyperresponsive to chronic mild hypoxia. J Clin Invest 1998, 103:291-299.
49. Cooper AL, Beasley D: Hypoxia stimulates proliferation and interleukir-1 alpha production in human vascular smooth muscle cells. Am J Physiol 1999, H1326-H1337.
50. Ambalavanan N, Bulger A, Philips JB: Hypoxia-induced release of peptide growth factors from neonatal porcine pulmonary artery smooth muscle cells. Biol Neonate 1999, 76:311-319.
51. Tozzi CA, Christiansen DL, Poiani GJ, et al: Excess collagen in hypertensive pulmonary arteries decreases vascular distensibiitiy. Am J Respir Crit Care Med 1994, 149:1317-1326.
52. Cowan KN, Heilbut A, Humpl T, et al: Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000, 6:698-702.
53. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
54. Dubin D, Pratt RE, Kooke JP, Dzau VJ: Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Biol Med 1989, 1:150-154.
55. Giaid A, Yanagisawa M, Langleben D, et al: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
56. Cacoub P, Dorent R, Nataf P, et al: Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997, 33:196-200.
57. Elton TS, Oparil S, Taylor GR, et al: Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992, 263:1260-1264.
58. Corbin JD, Francis SH: Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999, 274:13729-13732.
59. Zhao L, Mason NA, Morrell NW, et al: Sildenafil inhibits hypoxia induced pulmonary hypertension. Circulation 2001, 104:424-428.
60. Prasad S, Wilkinson J, Gateoulis MA: Sildenafil in primary pulmonary hypertension. N Engl J Med 2000, 343:1342.
61. Ghofrani H, Wiedermann R, Rose F, et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised, controlled, trial. Lancet 2002, 360:895-900.
62. Welsh SH, Hassell KL, Badesch DB, et al: Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996, 110:710-717.
63. Tuder RM, Cool CD, Geraci MW, et al: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925-1932.
64. Christman BW, McPherson CD, Newman JH, et al: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327:70-75.
65. Cella G, Bellotto F, Tona F, et al: Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001, 120:1226-1230.
66. Frank H, Milzoch J, Huber K, et al: The effect of anticoagulant therapy in primary and anorectic drug induced pulmonary hypertension. Chest 1997, 112:714-721.
67. Fuster V, Steele PM, Edwards WD, et al: Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 1984, 70:580-587.
68. Friedman R, Mears JG Barst RJ: Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997, 96:2782-2784.
69. Morelli S, Ferri C, Polettini E, et al: Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995, 99:255-260.
70. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Eng J Med 1995, 33:214-221.
71. Nong Z, Hoyberts M, Van Pelt M, et al: Nitric oxide inhalation inhibits platelets aggregation and platelet mediated pulmonary thrombosis in rats. Circ Res 1997, 81:865-869.
72. Tuder RM, Chacon M, Alger LA, et al: Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 2001, 195:367-374.
73. Eddahibi S, Humbert M, Fadel E, et al: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001, 108:1141-1150.
74. Fanburg BL, Lee SL: A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997, 272:L795-L806.
75. Lee SL, Wang WW, Lanzillo JJ, et al: Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994, 266:L46-L52.
76. Herve P, Launay J, Scrobohaci M, et al: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995, 249-254.
77. Maloney J, Silliman C, Ambruso DR, et al: In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998, 275:H1054-H1061.
78. Eddahibi S, Humbert M, Sediame S, et al: Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Resp Crit Care Med 2000, 162:1493-1499.
79. Rimar S, Gillis N: Selective pulmonary vasodilatation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993, 88:2884-2887.
80. Channick RN, Newhart JW, Johnson FW, et al: Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996, 109:1545.
81. Pepke-Zaba J, Higgenbottam TW, Dinh-Xuan AT, et al: Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991, 338:1173-1174.
82. Mikhail G, Gibbs J, Richardson M, et al: An evaluation of nebulised prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997, 18:1499-1504.
83. Olschewski H, Simmoneau G, Galie N, et al: Inhaled lloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
84. Hoeper M, Galie N, Simonneau G, et al: New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2000, 165:1209-1216.
85. Williamson DJ, Wallman LL, Jones R, et al: Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000, 102:411-418.
86. Channick RN, Simoneau G, Sitbon O, et al: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001, 358:1119-1123.
87. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.